Candel Therapeutics (CADL) Boosts Cash to $217M, Prepares for 2026 Prostate Cancer Launch
Candel Therapeutics, Inc. (NASDAQ:CADL) is a clinical-stage biopharmaceutical company pioneering the next generation of cancer immunotherapies by harnessing…